Cargando…

A retrosynthetic biology approach to metabolic pathway design for therapeutic production

BACKGROUND: Synthetic biology is used to develop cell factories for production of chemicals by constructively importing heterologous pathways into industrial microorganisms. In this work we present a retrosynthetic approach to the production of therapeutics with the goal of developing an in situ dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbonell, Pablo, Planson, Anne-Gaëlle, Fichera, Davide, Faulon, Jean-Loup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163555/
https://www.ncbi.nlm.nih.gov/pubmed/21819595
http://dx.doi.org/10.1186/1752-0509-5-122
_version_ 1782210960424960000
author Carbonell, Pablo
Planson, Anne-Gaëlle
Fichera, Davide
Faulon, Jean-Loup
author_facet Carbonell, Pablo
Planson, Anne-Gaëlle
Fichera, Davide
Faulon, Jean-Loup
author_sort Carbonell, Pablo
collection PubMed
description BACKGROUND: Synthetic biology is used to develop cell factories for production of chemicals by constructively importing heterologous pathways into industrial microorganisms. In this work we present a retrosynthetic approach to the production of therapeutics with the goal of developing an in situ drug delivery device in host cells. Retrosynthesis, a concept originally proposed for synthetic chemistry, iteratively applies reversed chemical transformations (reversed enzyme-catalyzed reactions in the metabolic space) starting from a target product to reach precursors that are endogenous to the chassis. So far, a wider adoption of retrosynthesis into the manufacturing pipeline has been hindered by the complexity of enumerating all feasible biosynthetic pathways for a given compound. RESULTS: In our method, we efficiently address the complexity problem by coding substrates, products and reactions into molecular signatures. Metabolic maps are represented using hypergraphs and the complexity is controlled by varying the specificity of the molecular signature. Furthermore, our method enables candidate pathways to be ranked to determine which ones are best to engineer. The proposed ranking function can integrate data from different sources such as host compatibility for inserted genes, the estimation of steady-state fluxes from the genome-wide reconstruction of the organism's metabolism, or the estimation of metabolite toxicity from experimental assays. We use several machine-learning tools in order to estimate enzyme activity and reaction efficiency at each step of the identified pathways. Examples of production in bacteria and yeast for two antibiotics and for one antitumor agent, as well as for several essential metabolites are outlined. CONCLUSIONS: We present here a unified framework that integrates diverse techniques involved in the design of heterologous biosynthetic pathways through a retrosynthetic approach in the reaction signature space. Our engineering methodology enables the flexible design of industrial microorganisms for the efficient on-demand production of chemical compounds with therapeutic applications.
format Online
Article
Text
id pubmed-3163555
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31635552011-08-30 A retrosynthetic biology approach to metabolic pathway design for therapeutic production Carbonell, Pablo Planson, Anne-Gaëlle Fichera, Davide Faulon, Jean-Loup BMC Syst Biol Methodology Article BACKGROUND: Synthetic biology is used to develop cell factories for production of chemicals by constructively importing heterologous pathways into industrial microorganisms. In this work we present a retrosynthetic approach to the production of therapeutics with the goal of developing an in situ drug delivery device in host cells. Retrosynthesis, a concept originally proposed for synthetic chemistry, iteratively applies reversed chemical transformations (reversed enzyme-catalyzed reactions in the metabolic space) starting from a target product to reach precursors that are endogenous to the chassis. So far, a wider adoption of retrosynthesis into the manufacturing pipeline has been hindered by the complexity of enumerating all feasible biosynthetic pathways for a given compound. RESULTS: In our method, we efficiently address the complexity problem by coding substrates, products and reactions into molecular signatures. Metabolic maps are represented using hypergraphs and the complexity is controlled by varying the specificity of the molecular signature. Furthermore, our method enables candidate pathways to be ranked to determine which ones are best to engineer. The proposed ranking function can integrate data from different sources such as host compatibility for inserted genes, the estimation of steady-state fluxes from the genome-wide reconstruction of the organism's metabolism, or the estimation of metabolite toxicity from experimental assays. We use several machine-learning tools in order to estimate enzyme activity and reaction efficiency at each step of the identified pathways. Examples of production in bacteria and yeast for two antibiotics and for one antitumor agent, as well as for several essential metabolites are outlined. CONCLUSIONS: We present here a unified framework that integrates diverse techniques involved in the design of heterologous biosynthetic pathways through a retrosynthetic approach in the reaction signature space. Our engineering methodology enables the flexible design of industrial microorganisms for the efficient on-demand production of chemical compounds with therapeutic applications. BioMed Central 2011-08-05 /pmc/articles/PMC3163555/ /pubmed/21819595 http://dx.doi.org/10.1186/1752-0509-5-122 Text en Copyright ©2011 Carbonell et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology Article
Carbonell, Pablo
Planson, Anne-Gaëlle
Fichera, Davide
Faulon, Jean-Loup
A retrosynthetic biology approach to metabolic pathway design for therapeutic production
title A retrosynthetic biology approach to metabolic pathway design for therapeutic production
title_full A retrosynthetic biology approach to metabolic pathway design for therapeutic production
title_fullStr A retrosynthetic biology approach to metabolic pathway design for therapeutic production
title_full_unstemmed A retrosynthetic biology approach to metabolic pathway design for therapeutic production
title_short A retrosynthetic biology approach to metabolic pathway design for therapeutic production
title_sort retrosynthetic biology approach to metabolic pathway design for therapeutic production
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163555/
https://www.ncbi.nlm.nih.gov/pubmed/21819595
http://dx.doi.org/10.1186/1752-0509-5-122
work_keys_str_mv AT carbonellpablo aretrosyntheticbiologyapproachtometabolicpathwaydesignfortherapeuticproduction
AT plansonannegaelle aretrosyntheticbiologyapproachtometabolicpathwaydesignfortherapeuticproduction
AT ficheradavide aretrosyntheticbiologyapproachtometabolicpathwaydesignfortherapeuticproduction
AT faulonjeanloup aretrosyntheticbiologyapproachtometabolicpathwaydesignfortherapeuticproduction
AT carbonellpablo retrosyntheticbiologyapproachtometabolicpathwaydesignfortherapeuticproduction
AT plansonannegaelle retrosyntheticbiologyapproachtometabolicpathwaydesignfortherapeuticproduction
AT ficheradavide retrosyntheticbiologyapproachtometabolicpathwaydesignfortherapeuticproduction
AT faulonjeanloup retrosyntheticbiologyapproachtometabolicpathwaydesignfortherapeuticproduction